Palvella Therapeutics' Qtorin Granted FDA Rolling Review; Shares Rise Pre-Bell

MT Newswires Live06-22

Palvella Therapeutics (PVLA) said Monday that the US Food and Drug Administration has granted rolling review for its New Drug Application for Qtorin rapamycin to treat microcystic lymphatic malformations.

Microcystic lymphatic malformations are a rare, chronically debilitating genetic disease caused by dysregulation of the PI3K/mTOR pathway. The malformed lymphatic vessels can protrude through the skin, persistently leak and bleed, and cause recurrent infections, cellulitis, and hospitalization.

"We remain on track to complete submission of the Qtorin rapamycin NDA in the second half of 2026 and intend to utilize the benefits of rolling review, Breakthrough Therapy and Fast Track designations to support an efficient path toward potential approval," Chief Executive Wes Kaupinen said in a statement.

Shares of the biopharmaceutical company were up 5% pre-bell.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment